Midwest Professional Planners LTD. Reduces Holdings in Boston Scientific Corporation $BSX

Midwest Professional Planners LTD. trimmed its position in shares of Boston Scientific Corporation (NYSE:BSX) by 56.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,827 shares of the medical equipment provider’s stock after selling 22,774 shares during the period. Midwest Professional Planners LTD.’s holdings in Boston Scientific were worth $761,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of BSX. Kelleher Financial Advisors acquired a new position in shares of Boston Scientific in the second quarter worth about $25,000. FWL Investment Management LLC acquired a new position in shares of Boston Scientific in the 2nd quarter valued at approximately $26,000. Swiss RE Ltd. purchased a new position in shares of Boston Scientific during the 4th quarter valued at approximately $26,000. Garton & Associates Financial Advisors LLC bought a new stake in shares of Boston Scientific in the fourth quarter worth $26,000. Finally, Clal Insurance Enterprises Holdings Ltd bought a new position in Boston Scientific during the 1st quarter valued at $28,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

BSX has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $60.00 target price on shares of Boston Scientific in a research report on Thursday, July 30th. Canaccord Genuity Group cut their price objective on Boston Scientific from $70.00 to $66.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Jefferies Financial Group decreased their target price on Boston Scientific from $100.00 to $67.00 and set a “buy” rating for the company in a research report on Wednesday, June 24th. Truist Financial dropped their price target on Boston Scientific from $62.00 to $57.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Finally, Stifel Nicolaus set a $60.00 price objective on Boston Scientific in a research note on Wednesday, July 29th. Twenty-four analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $71.62.

Boston Scientific Trading Down 0.5%

NYSE:BSX opened at $48.05 on Wednesday. Boston Scientific Corporation has a 12-month low of $42.20 and a 12-month high of $109.50. The firm has a market capitalization of $69.64 billion, a P/E ratio of 19.45, a P/E/G ratio of 1.12 and a beta of 0.57. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The business has a 50 day simple moving average of $46.69 and a 200 day simple moving average of $56.17.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same period last year, the company earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities research analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific declared that its Board of Directors has initiated a share buyback plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director David C. Habiger bought 2,100 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were purchased at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the transaction, the director directly owned 17,160 shares in the company, valued at $816,644.40. The trade was a 13.94% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward J. Ludwig purchased 5,000 shares of Boston Scientific stock in a transaction on Friday, July 31st. The shares were acquired at an average price of $45.48 per share, with a total value of $227,400.00. Following the transaction, the director directly owned 30,359 shares in the company, valued at $1,380,727.32. This trade represents a 19.72% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have bought 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is owned by company insiders.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.